Nine publications [12, 17, 21, 30, 33–37] stated that chronicled hepatic fibrosis observed significant attenuation in expression levels of alpha-1 type 1 collagen (COL1A1), TGF-β1, tissue inhibitor of metalloproteinase-1 (TIMP-1), matrix metalloproteinase-2 (MMP-2), and α-smooth muscle actin (α-SMA) owing to ACs, such as LMWH (e.g., enoxaparin), NOACs (argatroban and rivaroxaban), thrombin inhibitor (dabigatran), and antiplatelet agent (aspirin). This evidence concerns the gene COL1A1 and Hepatic fibrosis.